The quarter came in modestly worse than the earnings bar. Olema reported a $0.61 per-share loss versus published estimates clustered around roughly $0.55–$0.56, making the bottom-line result a small miss rather than a clean in-line quarter.
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Net loss | $(63.2) million (Income Statement) | $(43.8) million (Income Statement) | Loss widened 44% year over year |
| Loss per share | $(0.61) (Income Statement) | $(0.51) (Income Statement); published consensus ~$(0.55)–$(0.56) | Narrow miss versus expectation |
| R&D expense | $57.8 million (Income Statement) | $43.9 million (Income Statement) | Up 32% as late-stage trials ramped |
| G&A expense | $9.4 million (Income Statement) | $4.0 million (Income Statement) | More than doubled amid infrastructure and commercial preparation |
| Cash, equivalents and marketable securities | $461.1 million (Balance Sheets Data) | $505.4 million at December 31, 2025 (Balance Sheets Data) | Down $44.4 million in six months |
The core clinical update is constructive, but largely execution rather than new efficacy evidence. Enrollment is complete in the pivotal OPERA-01 trial, and the company now expects top-line data in the first quarter of 2027 (Recent Progress; Anticipated Upcoming Events). That removes enrollment risk and establishes a defined catalyst, but the filing provides no new palazestrant efficacy or safety data to reduce the main binary risk ahead of the readout.
The pipeline broadened through Bayer, but the near-term value remains concentrated in palazestrant. The OP-3136 collaboration with Bayer and initial Phase 1 evidence of tolerability and anti-tumor activity add optionality (Recent Progress). However, OP-3136 remains an early-stage asset, while the commercially relevant value proposition still depends primarily on the two Phase 3 palazestrant programs (About OP-3136; About Palazestrant).
Olema is spending aggressively to reach late-stage and commercial milestones. GAAP R&D rose to $57.8 million, and even excluding stock compensation, R&D increased to $48.9 million from $40.2 million (R&D reconciliation). G&A also rose to $9.4 million, including preparations for potential future commercial operations (G&A reconciliation). The spending is strategically understandable, but it contributed to the EPS miss and reduced cash from $505.4 million at year-end 2025 to $461.1 million at June 30, 2026 (Balance Sheets Data).
Net read: mixed. The completed OPERA-01 enrollment and Bayer collaboration improve execution visibility, but the filing delivers no new late-stage clinical proof, while losses and cash usage were heavier than investors expected. The key picture is therefore unchanged rather than decisively improved: a better-defined 2027 catalyst, funded by a shrinking but still substantial cash position, with the main clinical outcome still ahead.
Read the original 8-K on SEC EDGAR ↗